imipramine has been researched along with Weight Gain in 12 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 9.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 5.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| " Three tricyclic antidepressants examined (imipramine, clomipramine and desipramine) did not seem to have the side effect of pathological weight gain in the frequency distribution pattern." | 5.07 | Changes in the frequency distribution pattern of body weight in patients with major depression. ( Kato, T; Murashita, J; Shioiri, T; Takahashi, S; Yamada, N, 1993) |
| "Nefazodone treatment was associated with fewer side effects than were the control drugs." | 2.39 | The safety profile of nefazodone. ( Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996) |
| " Acute and chronic administration of psychotropic drugs (imipramine and chlordiazepoxide) showed that treatment with imipramine increased both the number of lever presses and successful escapes while chlordiazepoxide increased only the number of lever presses." | 1.29 | Evaluation of depression in rats exposed to chronic (unpredictable) electric shock. ( Hara, C; Naruo, T; Nozoe, S; Ogawa, N; Tanaka, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naruo, T | 1 |
| Hara, C | 1 |
| Nozoe, S | 1 |
| Tanaka, H | 1 |
| Ogawa, N | 1 |
| Shioiri, T | 1 |
| Kato, T | 1 |
| Murashita, J | 1 |
| Yamada, N | 1 |
| Takahashi, S | 1 |
| Robinson, DS | 1 |
| Roberts, DL | 1 |
| Smith, JM | 1 |
| Stringfellow, JC | 1 |
| Kaplita, SB | 1 |
| Seminara, JA | 1 |
| Marcus, RN | 1 |
| Fogelson, DL | 1 |
| Cash, TF | 1 |
| Brown, MA | 1 |
| Mavissakalian, MR | 1 |
| Perel, JM | 1 |
| Sussman, N | 1 |
| Ginsberg, DL | 1 |
| Bikoff, J | 1 |
| Frank, E | 2 |
| Kupfer, DJ | 3 |
| Buhari, A | 1 |
| McEachran, AB | 1 |
| Grochocinski, VJ | 1 |
| Bulik, CM | 1 |
| Levenson, JA | 1 |
| Noyes, R | 1 |
| Garvey, MJ | 1 |
| Cook, BL | 1 |
| Samuelson, L | 1 |
| Fernstrom, MH | 1 |
| McConaha, C | 1 |
| Brady, K | 1 |
| Zarzar, M | 1 |
| Lydiard, RB | 1 |
2 reviews available for imipramine and Weight Gain
| Article | Year |
|---|---|
The safety profile of nefazodone.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agent | 1996 |
Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Controlled | 2001 |
5 trials available for imipramine and Weight Gain
| Article | Year |
|---|---|
Changes in the frequency distribution pattern of body weight in patients with major depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Body Weight; Clomipramine; Depressive Disorder; Desipramine | 1993 |
Attitudes about antidepressants: influence of information about weight-related side effects.
Topics: Adolescent; Adult; Antidepressive Agents; Attitude to Health; Body Weight; Drug Information Services | 2000 |
The side effects burden of extended imipramine treatment of panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Blood Pressure; Female; Heart Rate; Humans; Im | 2000 |
Imipramine and weight gain during the long-term treatment of recurrent depression.
Topics: Adult; Body Mass Index; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Imipr | 1992 |
Imipramine and weight gain during the treatment of recurrent depression.
Topics: Adult; Body Mass Index; Combined Modality Therapy; Depressive Disorder; Dose-Response Relationship, | 1990 |
5 other studies available for imipramine and Weight Gain
| Article | Year |
|---|---|
Evaluation of depression in rats exposed to chronic (unpredictable) electric shock.
Topics: Animals; Behavior, Animal; Conditioning, Operant; Depression; Diazepam; Electroshock; Helplessness, | 1993 |
Fenfluramine and the cytochrome P450 system.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fenfl | 1997 |
Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study.
Topics: Adult; Agoraphobia; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Anxiety Disorders; Ap | 1989 |
Perception of appetite and weight change during treatment for depression.
Topics: Adult; Appetite; Body Image; Depression; Feeding Behavior; Female; Humans; Imipramine; Male; Middle | 1989 |
Fluoxetine in panic disorder patients with imipramine-associated weight gain.
Topics: Adult; Agoraphobia; Depressive Disorder; Fear; Female; Fluoxetine; Humans; Imipramine; Middle Aged; | 1989 |